A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.
AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen and nutrients to grow.
Inclusion Criteria:
Exclusion Criteria:
ItajaÃ-, Santa Catarina 88301-220, Brazil
São Paulo, São Paulo 01317-000, Brazil
Orléans Cedex 2, 45067, France
Périgueux Cedex, 24004, France
Saint Grégoire Cedex, 35768, France
Hyderabad, Andhra Pradesh 500 024, India
Hidaka-Shi, Saitama 350-1298, Japan
Suntou-gun, Shizuoka 411-8777, Japan
Chuo-ku, Tokyo 104-0045, Japan
Distrito Federal, Mexico City 04380, Mexico
Goyang-si, Gyeonggi-do, 410-769, South Korea
Córdoba, AndalucÃ-a 14004, Spain
Málaga, AndalucÃ-a 29010, Spain
San Sebastián, PaÃ-s Vasco 20014, Spain
Umeå, 901 85, Sweden